- Home
- CMA vs HALO Comparison
CMA vs HALO Comparison
Compare CMA & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMA | HALO |
|---|---|---|
| Founded | 1849 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 7.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CMA | HALO |
|---|---|---|
| Price | $88.26 | $65.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 22 | 12 |
| Target Price | $71.86 | ★ $73.33 |
| AVG Volume (30 Days) | 1.5M | ★ 2.5M |
| Earning Date | 01-21-2026 | 11-03-2025 |
| Dividend Yield | ★ 3.24% | N/A |
| EPS Growth | 30.50 | ★ 56.68 |
| EPS | ★ 5.23 | 4.74 |
| Revenue | ★ $3,234,000,000.00 | $1,242,852,000.00 |
| Revenue This Year | $6.42 | $34.83 |
| Revenue Next Year | $3.03 | $24.84 |
| P/E Ratio | $16.78 | ★ $13.61 |
| Revenue Growth | 2.31 | ★ 31.19 |
| 52 Week Low | $48.12 | $46.26 |
| 52 Week High | $90.44 | $79.50 |
Technical Indicators
Market Signals| Indicator | CMA | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 71.35 | 48.84 |
| Support Level | $87.41 | $61.23 |
| Resistance Level | $90.44 | $63.26 |
| Average True Range (ATR) | 1.72 | 2.23 |
| MACD | 0.46 | -0.09 |
| Stochastic Oscillator | 79.56 | 38.97 |
Price Performance
Historical ComparisonAbout CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.